Home
About
Technology
Pipeline
Partners
Investors
News + Resources
- News
- Resource Library
Menu Menu

IJCAHPO 2021 Post Video Form

Clinical Results: MydCombi Efficacy and Safety

Please complete the form below and share any questions you may have for James Tsai, MD

Your Name(Required)

Your Email(Required)

Questions for James Tsai, MD | Clinical Results: MydCombi Efficacy and Safety

Recent Posts

Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform May 8, 2023
Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update March 30, 2023
Eyenovia Announces Independent Director Stephen Benjamin To Step Down To Assume Role Of Head Of White House’s Office Of Public Engagement March 2, 2023

Pipeline and Technology

MydCombi (Mydriasis)
MicroLine (Presbyopia)
MicroPine (Myopia)
Technology

Corporate Address

Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com

Copyright © 2023 Eyenovia, Inc. All rights reserved.

Twitter
Facebook
LinkedIn

Contact
Safe Harbor
Privacy Policy
Terms of Use